Table 3. Patients with a discordant KRAS status between primary tumour and liver metastasis. Multiple blocks of primary tumour tissue and lymph node metastases were tested when available.
| KRAS status primary tumour | KRAS status 2nd tumour | KRAS status lymph node metastasis | KRAS status liver metastasis | |
|---|---|---|---|---|
| 1 | Gly12Ala | — | LN 1: Gly12Ala | WT |
| LN 2: Gly12Ala | ||||
| LN 3: Gly12Ala | ||||
| 2 | Gly12Asp | — | — | WT |
| Gly12Asp | ||||
| WT | ||||
| 3 | Gly12Cys | — | — | WT |
| 4 | Gly12Asp | — | LN 1: Gly12Asp | WT |
| Gly12Asp | LN 2: Gly12Asp | |||
| Gly12Asp | LN 3: Gly12Asp | |||
| Gly12Asp | LN 4: Gly12Asp | |||
| LN 5: WT | ||||
| 5 | Gly12Ser | — | — | WT |
| 6 | WT | — | — | Gly12Cys |
| 7 | Gly12Asp | — | LN 1: WT | Gly12Ala |
| LN 2: WT | ||||
| LN 3: WT | ||||
| 8 | Gly13Asp | Gly13Asp | LN 1: Gly13Asp | Gly12Ser |
| 9 | Gly12Ser | — | — | Gly12Ala |
| 10 | Gly12Cys | — | LN 1: Gly12Asp | Gly12Asp |
| Gly12Asp | LN 2: Gly12Asp | |||
| LN 3: Gly12Asp | ||||
| LN 4: Gly12Asp | ||||
| LN 5: Gly12Asp | ||||
| LN 6: WT | ||||
| 11 | Gly12Asp/Gly12Val | — | LN 1: Gly12Val | Gly12Asp |
| LN 2: Gly12Val | ||||
| LN 3: Gly12Val | ||||
| LN 4: Gly12Asp | ||||
| LN 5: Gly12Asp | ||||
| LN 6: Gly12Asp | ||||
| LN 7: Gly12Asp |
Abbreviation: WT=wild type.